A efficacy of maintenance intensification therapy by (Bevacizumab)/Pemetrexed/Carboplatin or Cisplatin after induction therapy by Erlotinib for EGFR mutation positive non -spuamous non-small cell lung cancer.

Trial Profile

A efficacy of maintenance intensification therapy by (Bevacizumab)/Pemetrexed/Carboplatin or Cisplatin after induction therapy by Erlotinib for EGFR mutation positive non -spuamous non-small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Erlotinib (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jul 2015 New trial record
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).
    • 02 Jun 2015 Primary endpoint (1-year Progression Free Survival rate) has not been met, according to abstract presented at ASCO 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top